

SYNTHESIS AND ANTIBACTERIAL ACTIVITY  
OF NEW DERIVATIVES OF 2-OXO-2,5-DIHYDROFURANS  
CONTAINING AN OXOTHIAZOLIDINYLIDENE RINGG. G. TOKMAJYAN <sup>1\*</sup>, L. V. KARAPETYAN <sup>1\*\*</sup>, R. V. PARONIKYAN <sup>2\*\*\*</sup>,  
H. M. STEPANYAN <sup>2\*\*\*\*</sup><sup>1</sup> Chair of Organic Chemistry YSU, Armenia<sup>2</sup> Scientific-Technological Center of Organic and  
Pharmaceutical Chemistry of NAS of the Republic of Armenia

New derivatives of 2-oxo-2,5-dihydrofurans containing an oxothiazolidinylidene ring were successfully synthesized based on thiosemicarbazones of 3-acetyl-2-oxo-2,5-dihydrofurans. The synthesized compounds exhibited moderate to defined antibacterial activities against Gram-positive (*Staphylococcus aureus* – 209p and 1) and Gram-negative (*Shigella Flexneri* 6858, *Esherichia coli* 0–55) bacteria compared to furazolidone.

**Keywords:** 3-acetyl-2-oxo-2,5-dihydrofurans, thiosemicarbazones, oxothiazolidinylidene ring synthesis, antibacterial activity.

**Introduction.** Functionally substituted derivatives of unsaturated  $\gamma$ -lactones have a wide range of biological activity and exhibit various pharmacological actions [1–9]. The biological activity of unsaturated  $\gamma$ -lactones is due to the presence of an unsaturated C=C bond or an aromatic substituent [10, 11]. Unsaturated  $\gamma$ -lactones conjugated to a double bond are also plant growth stimulators [12, 13].


The antibacterial activity of unsaturated  $\gamma$ -lactones can be explained by their ability to interact with bacterial proteins, as well as with certain enzymes containing sulfhydryl groups and which are of great importance for the normal life of microorganisms, which are known in unsaturated  $\gamma$ -lactone series [14, 15]. It is assumed that the bactericidal action of 2-oxo-2,5-dihydrofuranes is associated with the ability of the lactone double bond to attach the SH groups present in bacterial proteins, inhibiting the development of bacteria.

Thiazolidine derivatives are of great biological importance due to their anti-diabetic [16] and antibacterial [17] activity. One such compound, namely (*Z*)-*N*-(2-chloro-6-methylphenyl)-2-(3-methyl-4-oxo-1,3-thiazolidin-2-ylidene)acetamide (ralitoline), has been found to be effective in a preclinical anticonvulsant evaluation [18]. In view of the importance of 2-oxo-2,5-dihydrofuranes and 4-oxothiazolidin-2-ylidene ring, we described the synthesis and study of the antibacterial activity of the title compounds.

\* E-mail: [tokmajyan@ysu.am](mailto:tokmajyan@ysu.am)\*\* E-mail: [lkarapetyan@ysu.am](mailto:lkarapetyan@ysu.am)\*\*\* E-mail: [stepanyan-37@mail.ru](mailto:stepanyan-37@mail.ru)\*\*\*\* E-mail: [stepanyan-37@mail.ru](mailto:stepanyan-37@mail.ru)

**Results and Discussion.** New derivatives of 2-oxo-2,5-dihydrofurans containing an oxothiazolidinylidene ring – 2-((1-(4-methyl-5,5-dialkyl-2-oxo-2,5-dihydrofuran-3-yl)ethylidene)hydrazono)thiazolidin-4-ones (**3a–d**) were successfully synthesized by the condensation of thiosemicarbazones of 3-acetyl-2-oxo-2,5-dihydrofurans **1a–d** [19] with chloroacetic acid ethyl ester **2** in the presence of sodium acetate, taken in a molar ratio of 1: 1.5: 3 in absolute ethanol.

The structures of the obtained compounds were determined from their spectroscopic data. Compounds **1b** and **3b** have an asymmetric carbon atom. The specific rotation was measured for these compounds. They are optically inactive compounds.



Scheme.

The antibacterial activities of the starting **1a–d** and obtained **3a–d** compounds were evaluated against Gram-positive (*Staphylococcus aureus* – 209p and 1) and Gram-negative (*Shigella Flexneri* 6858, *Esherichia coli* 0–55) bacteria by the agar diffusion technique [20]. The antibacterial activities of compounds **1a–d** and **3a–d** were compared with the standard drug furazolidone [21].

*Antibacterial activities of 1 a–d and 3 a–d compounds in comparison to furazolidone*

| Compounds    | <i>Staphylococcus aureus</i> |          | <i>Shigell Flexneri</i><br>6858 | <i>Esherichia coli</i><br>0–55 |
|--------------|------------------------------|----------|---------------------------------|--------------------------------|
|              | 209p                         | 1        |                                 |                                |
|              | Zone of inhibition, mm       |          |                                 |                                |
| <b>1a</b>    | 10.0±0.1                     | 10.7±0.2 | 10.4±0.3                        | 9.0±0.4                        |
| <b>1b</b>    | 11.0±0.6                     | 10.0±0.7 | 10.4±0.5                        | 9.9±0.1                        |
| <b>1c</b>    | 6.0±0.3                      | 5.6±0.2  | 7.4±0.4                         | 8.0±0.1                        |
| <b>1d</b>    | 11.0±0.4                     | 6.7±0.4  | 11.4±0.1                        | 11.0±0.6                       |
| <b>3a</b>    | 16.3±0.6                     | 20.8±0.9 | 16.3±0.9                        | 17.0±1.4                       |
| <b>3b</b>    | 10.0±0                       | 10.0±0   | 13.0±1,0                        | 13.3±0,6                       |
| <b>3c</b>    | 12.6±0,6                     | 17.6±1,3 | 13.3±0,6                        | 13.0±1,0                       |
| <b>3d</b>    | 17.3±0,9                     | 10.0±1,0 | 16.0±1,0                        | 20.3±0,9                       |
| Furazolidone | 25±1.0                       | 24±1.2   | 24±1.0                          | 24±1.0                         |

The antibacterial activities of compounds **1a–d** and **3a–d** are shown in Table. In comparison to furazolidone, compounds **1a–d** exhibited weak activities towards the growth of both Gram-positive and Gram-negative bacteria. Replacing the carbothioamide group to oxothiazolidinylidene ring to compounds **3a–d** enhanced the antibacterial activity. Compounds **3a–d** exhibited moderate to defined activities.

### Experimental Part.

*Chemical Part.* The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded at 300 MHz and 75 MHz on a Varian Mercury-300 MHz spectrometer in the mixture of solvents  $\text{DMSO-}d_6+\text{CCl}_4$  (1 : 3) using tetramethylsilane as the internal standard and IR spectra on an Avatar 330FT-IR spectrometer using attenuated total reflectance (ATR) method. The reaction progress and the purity of the obtained substances were checked using TLC method on UV-254 plates with an acetone–benzene mixture (1 : 2) as an eluent, visualization with iodine vapors. All melting points were determined by measuring with an Electrothermal 9100 apparatus. Specific optical rotation was decided on a Polartronic H532 polarimeter.

Compound **1c** was synthesized by the known procedure [19].

2-((1-(4-Methyl-2-oxo-1-oxaspiro[4.4]non-3-en-3-yl)ethylidene)hydrazine-carbothioamide (**1c**). Yield 90%,  $R_f$  0.57, m.p. 156–158°C.  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm: 1.42 m (2H) and 1.58–1.85 m (6H,  $(\text{CH}_2)_4$ ), 2.27 s (6H, 2CH<sub>3</sub>), 7.62 br.s (1H, NH), 7.90 br.s (2H, C(S)NH<sub>2</sub>).

**General Procedure for the Preparation of Compounds 3 a–d.** To a well-stirred solution of compound **1 a–d** (4 mmol) and sodium acetate 0.74 g (12 mmol) in 10 mL absolute ethanol was added ethyl chloroacetate **2** 0.65 mL (6 mmol). The mixture was boiled for 10–12 h. The reaction mixture was cooled, water was added, stirred for 15 min, the precipitate was filtered off, washed with water.

2-((1-(4,5,5-Trimethyl-2-oxo-2,5-dihydrofuran-3-yl)ethylidene)hydrazono)-thiazolidin-4-one (**3a**). Yield 88%,  $R_f$  0.56, m.p. 218–220°C.  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm: 1.45 s (6H, 2CH<sub>3</sub>), 2.38 s (6H, 2CH<sub>3</sub>), 3.75 s (2H, CH<sub>2</sub>), 11.6 br.s (1H, NH).  $^{13}\text{C}$  NMR spectrum,  $\delta$ , ppm: 12.98 (2CH<sub>3</sub>), 15.58 (CH<sub>3</sub>), 24.16 (S–CH<sub>2</sub>), 32.45 (CH<sub>3</sub>), 84.47 (C<sub>5</sub>), 122.65 (C<sub>3</sub>), 155.88 (C<sub>4</sub>), 164.33 (C=N), 168.97 (C=N), 169.84 (C=O), 172.80 (C=O).

2-((1-(5-Ethyl-4,5-dimethyl-2-oxo-2,5-dihydrofuran-3-yl)ethylidene)hydrazono)thiazolidin-4-one (**3b**). Yield 87%,  $R_f$  0.55, m.p. 230–232°C,  $[\alpha]_D^{20}$  0 c (0.5, DMSO).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm: 0.75 t (3H,  $J$  7.3 Hz, CH<sub>2</sub>CH<sub>3</sub>), 1.44 s (3H, CH<sub>3</sub>), 1.78 d q (1H, CH<sub>2</sub>CH<sub>3</sub>,  $J$  14.6, 7.3 Hz), 1.94 d q (1H, CH<sub>2</sub>CH<sub>3</sub>,  $J$  14.6, 7.3 Hz), 2.38 s (6H, 2CH<sub>3</sub>), 3.74 c (2H, CH<sub>2</sub>), 11.69 br.s (1H, NH).  $^{13}\text{C}$  NMR spectrum,  $\delta$ , ppm: 6.92 (CH<sub>3</sub>), 11.99 (CH<sub>3</sub>), 15.51 (CH<sub>3</sub>), 23.27 (CH<sub>2</sub>), 29.64 (CH<sub>3</sub>), 32.49 (S–CH<sub>2</sub>), 84.49 (C<sub>5</sub>), 122.65 (C<sub>3</sub>), 155.88 (C<sub>4</sub>), 164.33 (C=N), 168.97 (C=N), 169.84 (C=O), 172.80 (C=O).

2-((1-(4-Methyl-2-oxo-1-oxaspiro[4.4]non-3-en-3-yl)ethylidene)hydrazono)-thiazolidin-4-one (**3c**). Yield 88%,  $R_f$  0.54, m.p. 190–192°C.  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm: 1.42 m (2H) and 1.58–1.85 m (6H,  $(\text{CH}_2)_4$ ), 2.38 s (6H, 2CH<sub>3</sub>), 3.75 s (2H, CH<sub>2</sub>), 11.8 br.s (1H, NH).  $^{13}\text{C}$  NMR spectrum,  $\delta$ , ppm: 15.68 (CH<sub>3</sub>), 22.10 (CH<sub>2</sub>), 22.22 (CH<sub>2</sub>), 25.09 (CH<sub>2</sub>), 26.95 (CH<sub>2</sub>), 27.13 (S–CH<sub>2</sub>), 40.24 (CH<sub>3</sub>), 83.64 (C<sub>5</sub>), 120.68 (C<sub>3</sub>), 155.64 (C<sub>4</sub>), 169.13 (C=N), 168.97 (C=N), 172.23 (C=O), 172.58 (C=O).

2-((1-(4-Methyl-2-oxo-1-oxaspiro[4.5]dec-3-en-3-yl)ethylidene)hydrazono)-thiazolidin-4-one (**3d**). Yield 85%,  $R_f$  0.54, m.p. 210–212°C.  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm: 1.42 m (2H) and 1.58–1.85 m (6H,  $(\text{CH}_2)_4$ ), 2.38 s (6H, 2CH<sub>3</sub>), 3.75 s (2H, CH<sub>2</sub>), 11.8 br.s (1H, NH).  $^{13}\text{C}$  NMR spectrum,  $\delta$ , ppm: 15.68 (CH<sub>3</sub>), 21.4 (2CH<sub>2</sub>), 23.8 (CH<sub>2</sub>), 32.3 (2CH<sub>2</sub>), 24.30 (S–CH<sub>2</sub>), 38.96 (CH<sub>3</sub>), 84.47 (C<sub>5</sub>), 122.65 (C<sub>3</sub>), 155.88 (C<sub>4</sub>), 164.33 (C=N), 168.97 (C=N), 170.84 (C=O), 172.80 (C=O).

**Biological Part.** The data were analyzed statistically using Student's and Fisher's tests. The antibacterial activities of the starting compounds **1 a–d** and the obtained compounds **3 a–d** were evaluated against Gram-positive (*Staphylococcus aureus* – 209p and 1) and Gram-negative (*Shigella Flexneri* 6858, *Esherichia coli* 0–55) bacteria by the agar diffusion technique with microbial loading  $20 \times 10^6$  microbes per mL of medium. Solutions of the tested compounds were prepared in DMSO at a 1 : 20 concentration and poured (0.1 mL) into cylinders placed on the surface of an agar medium inoculated with test strain in Petri dishes. The results were evaluated from the diameter ( $d$ , mm) of the microbe growth inhibition zone at the compound application site after growth for 20 h at 37°C. The tests were repeated three times. The zones of inhibition were measured in millimetre (mm) to estimate the potency of the test compound.

**Conclusion.** New derivatives of 2-oxo-2,5-dihydrofurans containing an oxo-thiazolidinylidene ring were successfully synthesized by the convenient and efficient method, based on the reaction of thiosemicarbazones of 3-acetyl-2-oxo-2,5-dihydrofurans with ethyl chloroacetate in the presence of sodium acetate. The synthesized compounds **3 a–d** exhibited moderate to defined antibacterial activities against Gram-positive (*Staphylococcus aureus* – 209p and 1) and Gram-negative (*Shigella Flexneri* 6858, *Esherichia coli* 0–55) bacteria compared to furazolidone.

Received 24.12.2019

Reviewed 21.02.2020

Accepted 10.04.2020

#### REFERENCES

1. Avetisyan A.A., Tokmadzhyan G.G. Chemistry of  $\Delta\beta,\gamma$ -Butenolides. *Khim. Geterotsikl. Soedin.*, **6** (1987), 723–739 (in Russian).
2. Avetissian A.A., Tokmajian G.G. Biologically Active Derivatives of 2-buten- and 3-buten-4-olides. *Chem. J. Arm.*, **3–4** (1993), 219–236 (in Russian).
3. Avetissyan A.A., Tokmajyan G.G. Achievement of Chemistry of 2-butene-4-olides. *Chem. J. Arm.*, **60** : 4 (2007), 698–712 (in Russian).
4. Laduwahetty T. Saturated and Unsaturated Lactones. *Contemp. Org. Synth.*, **2** (1995), 133–149.
5. Collins I. Saturated and Unsaturated Lactones. *Contemp. Org. Synth.*, **3** (1996), 295–321.
6. Srikrishna A., Sharma G.V.R. A Radical Cyclisation Route to ( $\pm$ )-Andirolactone, a Spiro- $\gamma$ -butyrolactone. *Tetrah. Lett.*, **29** : 49 (1988), 6487–6488.
7. Bonete P., Najera C. Lithium 3-Lithio-3-tosylalkanoates:  $\beta$ -Acylvinyl Anion Equivalents of  $\beta$ -Lithiated  $\alpha$ ,  $\beta$ -Unsaturated Carboxylic Acids. *J. Org. Chem.*, **59** : 11 (1994), 3202–3209.
8. Avetissyan A.A., Tokmadjyan G.G. Achievement of Chemistry of 2-butene-4-olides. *Chem. J. Arm.*, **60** : 4 (2007), 698–712 (in Russian).
9. Lattmann E., Dunn S., Niamsanit S., Sattayasai N. Synthesis and Antibacterial Activities of 5-hydroxy-4-amino-2(5H)-furanones. *Bioorg. Med. Chem. Lett.*, **15** : 4 (2005), 919–921.
10. Hollingworth G.J., Sweeney J.B. Preparation and Reactions of 3- and 4-tributylstannyl-2-(5H)-furanones: Preparation of Aryl Furanones. *Tetrahedron Lett.*, **33** : 46 (1992), 7049 p.
11. Dal Pozzo A., Dansi A., Mariotti V., Meneghini E. Relationships Between Constitution and Antimicrobial Activity of Gamma-lactones. *Bull. Chim. Farm.*, **111** : 6 (1972), 342–352.
12. Jansone D., Leite L., Fleisher M., Popelis J., Mazheika I., Lukevics E., Melikyan G., Avetisyan A. Reaction of Heterocyclic Aldehydes with Methyl Derivatives of Unsaturated  $\gamma$ - and  $\delta$ -lactones. *Khim. Geterotsikl. Soedin.*, **32** : 2 (1998), 186–192 (in Russian).
13. Avetisyan A.A., Akhnazaryan A.A., Melikyan G.S. Novel Reaction in the Field of Butanolides. *Chem. J. Arm.*, **41** : 12 (1988), 756–757 (in Russian).
14. Cavallito Ch.J., Haskell T.H. The Mechanism of Action of Antibiotics. The Reaction of Unsaturated Lactones with Cysteine and Related Compounds. *J. Am. Chem. Soc.*, **67** : 11 (1945), 1991–1994.

15. Cavallitto Ch.J., Fruehauf D.M., Bailey J.H. Lactone Aliphatic Acids as Antibacterial Agents. *J. Am. Chem. Soc.*, **70** : 11 (1948), 3724–3726.
16. Rizos C.V., Kei A., Elisaf M.S. The Current Role of Thiazolidinediones in Diabetes Management. *Arch. Toxicol.*, **90** (2016), 1861–1881.
17. Har D., Solensky R. Penicillin and Beta-Lactam Hypersensitivity. *Immunol. Allergy Clin. North Am.*, **37** (2017), 643–662.
18. Löscher W., Schmidt D. Strategies in Antiepileptic Drug Development: is Rational Drug Design Superior to Random Screening and Structural Variation? *Epilepsy Res.*, **17** (1994), 95–134.
19. Kasparyan B. Synthesis and Chemical Transformations of Some Unsaturated  $\delta$ - and  $\gamma$ -lactones. PhD Thesis., Yer., YSU (1985).
20. Marolova A.N. *Management on Carrying Out Preclinical Researches of Medicinal Agents*. M., Medicina (2012) (in Russian).
21. Mashkovski M.D. *Medicinal Agents*. M., Novaya Volna (2010) (in Russian).

Գ. Գ. ԹՈՔՄԱԶՅԱՆ, Լ. Վ. ԿԱՐԱՊԵՏՅԱՆ, Ր. Վ. ՊԱՐՈՆԻԿՅԱՆ, Հ. Մ. ՍՏԵՓԱՆՅԱՆ

**2-ՕՔՍՈ-2,5-ԴԻՀԻԴՐՈՖՈՒՐԱՆՆԵՐԻ  
ՕՔՍՈԹԻԱԶՈԼԻԴԻՆԻԼԻԴԵՆՈՎԵ ՕՂԱԿ ՊԱՐՈՒՆԱԿՈՂ ՆՈՐ  
ԱԾԱՆՅՅԱԼՆԵՐԻ ՍԻՆԹԵԶ ԵՎ ՀԱԿԱՄԱՆՐԷԱՅԻՆ ԱԿՏԻՎՈՒԹՅԱՆ  
ՈՒՍՈՒՄՆԱՍԻՐՈՒԹՅՈՒՆ**

**Ա մ փ ո փ ու մ**

2-Օքսո-2,5-դիհիդրոֆուրանների օքսոթիազոլիդինիլիդենային օղակ պարունակող նոր ածանցյալները հաջողությամբ սինթեզվել են 3-ացետիլ-2-օքսո-2,5-դիհիդրոֆուրանների թիոսեմիկարբազոնների հիմքի վրա: Սինթեզված միացությունները ցուցաբերում են չափավոր կամ արտահայտված հակամանր է ալին ակտիվություն գրամ-դրական (*Staphylococcus aureus* – 209p, 1) և գրամ-բացասական (*Shigella Flexneri* 6858, *Esherichia coli* 0–55) մանրէային շտամների նկատմամբ համեմատած որպես էտալոն ընտրված ֆուրազոլիդինի հետ:

Գ. Գ. ԹՈՔՄԱԶՅԱՆ, Լ. Վ. ԿԱՐԱՊԵՏՅԱՆ, Ր. Վ. ՊԱՐՈՆԻԿՅԱՆ, Հ. Մ. ՍՏԵՓԱՆՅԱՆ

**СИНТЕЗ И ИЗУЧЕНИЕ АНТИБАКТЕРИАЛЬНОЙ АКТИВНОСТИ  
НОВЫХ ПРОИЗВОДНЫХ 2-ОКСО-2,5-ДИГИДРОФУРАНОВ,  
СОДЕРЖАЩИХ ОКСОТИАЗОЛИДИНИЛИДЕНОВОЕ КОЛЬЦО**

**Резюме**

Новые производные 2-оксо-2,5-дигидрофуранов, содержащие оксотиазолидинилиденовое кольцо, синтезированы на основе тиосемикарбазонов 3-ацетил-2-оксо-2,5-дигидрофуранов. По сравнению с выбранным в качестве эталона фуразолидоном, синтезированные соединения проявляют умеренную или выраженную антибактериальную активность против грамположительных (*Staphylococcus aureus* – 209p и 1) и грамотрицательных (*Shigella Flexneri* 6858, *Esherichia coli* 0–55) бактерий.